March 21 (SeeNews) - Bulgarian pharmaceuticals producer Sopharma [BUL:SFA] said its sales revenue fell by 3% on the year in the first two months of 2024 on the back of lower exports.
Revenue from export sales went down by 7% year-on-year in January-February, whereas sales on the domestic market grew by 2%, Sopharma said in a bourse filing on Wednesday.
In February alone, Sopharma posted a 29% annual drop in sales revenue. The company's export sales sank by 43% on the year, while domestic sales lost 9%.
As of 1028 CET on Thursday, shares in Sopharma traded flat at 6.36 levs ($3.53/3.25 euro) on the Bulgarian Stock Exchange.
(1 euro = 1.95583 levs)